GLP-1-based Strategies: a Physiological Analysis of Differential Mode of Action
Overview
Authors
Affiliations
DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
Alharbi S Ther Adv Endocrinol Metab. 2024; 15:20420188231222367.
PMID: 38288136 PMC: 10823863. DOI: 10.1177/20420188231222367.
Correia A, Pereira S, Morais T, Martins A, Monteiro M, Alves M Biomedicines. 2022; 10(10).
PMID: 36289871 PMC: 9599882. DOI: 10.3390/biomedicines10102609.
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
Diz-Chaves Y, Mastoor Z, Spuch C, Gonzalez-Matias L, Mallo F Int J Mol Sci. 2022; 23(17).
PMID: 36076972 PMC: 9455625. DOI: 10.3390/ijms23179583.
A Novel Bacterium, , Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice GLP-1 Receptor.
Lee H, An J, Kim J, Choi D, Song Y, Lee C Front Microbiol. 2022; 13:858192.
PMID: 35655996 PMC: 9152154. DOI: 10.3389/fmicb.2022.858192.
Xie H, Yepuri N, Meng Q, Dhawan R, Leech C, Chepurny O Rev Endocr Metab Disord. 2020; 21(4):431-447.
PMID: 32851581 PMC: 7572644. DOI: 10.1007/s11154-020-09584-3.